Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Kristy J. Gotink(Amsterdam UMC Location VUmc), Henk M.W. Verheul(Erasmus MC Cancer Institute)
Cited by 488
Related Papers
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|788
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
|Nature reviews. Cancer|2007|502
Platelet: transporter of vascular endothelial growth factor.
|PubMed|1997|379
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
|Nature Communications|2020|238